Assay News and Research

RSS

Researchers found a curious mitochondrial pattern in people who moved more

Researchers found that greater self-reported activity, walking, and accelerometer-measured light activity were associated with higher mitochondrial DNA copy number in 256 healthy middle-aged adults. The cross-sectional findings cannot establish causation, and the very low amount of vigorous activity means they do not show that light movement is more beneficial than higher-intensity exercise.

29 Sep 2026

Bile DNA sequencing helps identify hidden pancreatobiliary tumors

Distinguishing malignant from benign biliary strictures remains a major clinical challenge. Endoscopic retrograde cholangiopancreatography (ERCP)-guided cytology and biopsy may be inconclusive, particularly in early-stage disease or when tissue is scarce.

29 Sep 2026

Menopause leaves a blood protein signature linked to brain aging and Alzheimer’s risk

Researchers identified a 16-protein blood signature associated with menopause that tracked more strongly with reproductive hormones than chronological age and was largely replicated in an independent UK Biobank cohort. Higher menopause proteomic scores were also associated with less favorable proteomic aging estimates and poorer cognitive outcomes in older women, including incident Alzheimer’s dementia, although the observational evidence does not establish causality.

23 Sep 2026

A chemical used in BPA-free products may have a connection to diabetes control

In adults with type 2 diabetes receiving oral glucose-lowering therapy, higher plasma BPS concentrations were associated with higher HbA1c after accounting for demographic factors, medication adherence, and diet, whereas BPA was not associated with HbA1c. The BPS association was modest and no longer statistically significant after further adjustment for BPA, BMI, and physical fitness, supporting the need for larger studies to determine whether reducing exposure could improve glycemic control.

23 Sep 2026

Designing fluidic architecture for scalable diagnostic platforms

Smarter fluidics decisions can reduce redesigns, improve reliability, and help diagnostic platforms perform consistently at scale.

From Fluid Metering, Inc. 23 Sep 2026

Regular exercisers show distinct metabolic and immune signatures in blood

Researchers compared blood samples from 40 regular exercisers and 46 sedentary adults and found differences in metabolites, blood chemistry, and immune cell gene activity. The patterns suggested greater fatty acid use and altered immune signaling among exercisers, but the study could not establish that exercise caused these differences.

21 Sep 2026

Researchers mine cobra toxins to uncover a membrane-disrupting antimicrobial peptide

Researchers combined toxin sequence mining with machine learning and deep-learning prediction tools to identify and experimentally test 14 antimicrobial peptide candidates derived from cobra cardiotoxins. Most candidates showed limited antibacterial potency, while CTX-p5 displayed moderate membrane-disrupting activity, revealing both the potential and current limitations of computationally guided venom peptide discovery.

17 Sep 2026

ACROBiosystems deepens its France presence with a dedicated hub at The HIVE Innovation Center, embedding into the Campus Grand Parc ecosystem

Kadans Science Partner is pleased to welcome ACROBiosystems to The HIVE Innovation Center, its laboratory and office building dedicated to the life sciences, situated on the Campus Grand Parc in Villejuif.

From ACROBiosystems 16 Sep 2026

Malvern Panalytical launches Zetasizer Core – an industry first in biologics plate-based stability screening

Malvern Panalytical's Zetasizer Core integrates DLS, SLS, and DSF in one platform, streamlining biologics discovery with unmatched efficiency and precision.

From Malvern Panalytical 15 Sep 2026

APOE genotype helps p-tau217 predict who may develop cognitive impairment sooner

A pooled analysis of 8,582 adults from seven prospective cohorts found that higher plasma p-tau217 concentrations were associated with greater cognitive impairment risk and earlier progression, with stronger associations among APOE-ε4 carriers. Each 1-SD increase in p-tau217 was associated with a 24% shorter time to cognitive impairment among carriers compared with 13% among non-carriers, suggesting that genetic background can refine the prognostic meaning of this Alzheimer’s disease blood biomarker.

14 Sep 2026

Innovative device improves real-time monitoring of donated lungs

More than three-quarters of donated lungs offered for transplantation are not used, according to the UK's National Institute for Health and Care Excellence, contributing to a chronic shortage of organs for patients with end-stage lung disease.

10 Sep 2026

Review highlights solute carriers as targets for central nervous system disorders

Solute carriers (SLCs) are specialized transport proteins that control the movement of nutrients, ions and neurotransmitters across cell membranes and are essential for brain metabolism and neuronal communication.

10 Sep 2026

Yourgene Health launches Insight DPYD assay (IVDR)

Yourgene Health (part of the Novacyt Group), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces the commercial launch of its In Vitro Diagnostic Regulation (IVDR)-certified Yourgene® Insight DPYD assay, expanding the Company's clinical genetics portfolio across regulated European markets.

From Yourgene Health 9 Sep 2026

Blood protein profiling could improve rare disease diagnosis

Researchers from Queen Mary University of London, the Berlin Institute of Health at Charité (BIH) and Genomics England have shown that measuring proteins in the blood can provide important additional clues about the effects of genetic variants, helping to identify diagnoses and potential new disease-causing genes that genome sequencing alone has been unable to resolve.

9 Sep 2026

New study uncovers bacterial route to testosterone production

Many prostate cancers depend on androgen hormones, including testosterone, to grow. That is why treatments for advanced disease often try to reduce testosterone production or block its effects.

4 Sep 2026

Genetic marker links popular seizure drug to life-threatening reaction

A genetic marker already used to flag risk of a life-threatening reaction to the antibiotic vancomycin also identifies patients at risk of that reaction to lamotrigine - and it is missing from the gene panels clinicians order before prescribing the drug, Vanderbilt Health-led researchers report Sept. 2 in JAMA Network Open.

2 Sep 2026

Monod Bio licenses AI-designed protein technologies to SignalChem Biotech for custom discovery assays

Monod Bio, a Seattle-based AI-enabled protein design company, and SignalChem Biotech Inc., a wholly-owned subsidiary of Sino Biological, Inc., today announced a non-exclusive licensing agreement covering Monod Bio’s proprietary LuxSit de novo luciferase technology and NovoBodies.

From Sino Biological Inc. 27 Aug 2026

FDA endorses alpha-synuclein biomarker for Parkinson’s clinical trials

Critical Path Institute® (C-Path) today announced the publication of "Regulatory endorsement for the application of alpha-synuclein seed amplification assay (αSyn-SAA) as a susceptibility and risk biomarker for clinical trials targeting synucleinopathies" in the Journal of Parkinson's Disease, marking a significant milestone for its Critical Path for Parkinson's consortium.

25 Aug 2026

Antibodies for visualizing cell identity and tumor architecture

Whether you are characterizing cell state transitions, assessing organelle integrity, or building a multiplex immunofluorescence (IF) assay, you need reliable structural markers for your imaging.

From Antibodies Incorporated 21 Aug 2026

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The ELRIG Mid-Career Initiative supports scientists in drug discovery, addressing unique challenges and fostering leadership development for career transitions.

20 Aug 2026